» Articles » PMID: 22430056

Pathogenesis of IgA Nephropathy

Overview
Journal Nat Rev Nephrol
Specialty Nephrology
Date 2012 Mar 21
PMID 22430056
Citations 109
Authors
Affiliations
Soon will be listed here.
Abstract

Since its first description in 1968, IgA nephropathy has remained the most common form of idiopathic glomerulonephritis leading to chronic kidney disease in developed countries. The exact pathogenesis of IgA nephropathy is still not well defined. Current data implicate an important genetic factor, especially in promoting the overproduction of an aberrant form of IgA1. The immunochemical aberrancy of IgA nephropathy is characterized by the undergalactosylation of O-glycans in the hinge region of IgA1. However, such aberrant glycosylation alone does not cause renal injury. The next stage of disease development requires the formation of glycan-specific IgG and IgA antibodies that recognize the undergalactosylated IgA1 molecule. These antibodies often have reactivity against antigens from extrinsic microorganisms and might arise from recurrent mucosal infection. B cells that respond to mucosal infections, particularly tonsillitis, might produce the nephritogenic IgA1 molecule. With increased immune-complex formation and decreased clearance owing to reduced uptake by the liver, IgA1 binds to the glomerular mesangium via an as yet unidentified receptor. Glomerular IgA1 deposits trigger the local production of cytokines and growth factors, leading to the activation of mesangial cells and the complement system. Emerging data suggest that mesangial-derived mediators following glomerular deposition of IgA1 lead to podocyte and tubulointerstitial injury via mesangio-podocytic-tubular crosstalk. This Review summarizes the latest findings in the pathogenesis of IgA nephropathy.

Citing Articles

Post-transplant IgA nephropathy: a rapidly evolving field of kidney transplant medicine.

Kanbay M, Ozbek L, Guldan M, Copur S, Barratt J J Nephrol. 2024; .

PMID: 39565563 DOI: 10.1007/s40620-024-02149-6.


An inflammatory cytokine signature predicts IgA nephropathy severity and progression.

Chen L, Chen X, Cai G, Jiang H, Chen X, Zhang M MedComm (2020). 2024; 5(11):e783.

PMID: 39492831 PMC: 11531656. DOI: 10.1002/mco2.783.


Therapy of IgA nephropathy: time for a paradigm change.

Barratt J, Lafayette R, Floege J Front Med (Lausanne). 2024; 11:1461879.

PMID: 39211339 PMC: 11358106. DOI: 10.3389/fmed.2024.1461879.


Uromodulin and progression of IgA nephropathy.

Chen Z, Xu L, Du W, Ouyang Y, Gu X, Fang Z Clin Kidney J. 2024; 17(8):sfae209.

PMID: 39145144 PMC: 11322676. DOI: 10.1093/ckj/sfae209.


Insights into non-coding RNAS: biogenesis, function and their potential regulatory roles in acute kidney disease and chronic kidney disease.

Li S, Hu W, Qian L, Sun D Mol Cell Biochem. 2024; 480(3):1287-1304.

PMID: 39110280 PMC: 11842482. DOI: 10.1007/s11010-024-05083-0.


References
1.
Zhu L, Tang W, Li G, Lv J, Ding J, Yu L . Interaction between variants of two glycosyltransferase genes in IgA nephropathy. Kidney Int. 2009; 76(2):190-8. DOI: 10.1038/ki.2009.99. View

2.
Lai K, Ho R, Lai C, Chan C, Li P . Increase of both circulating Th1 and Th2 T lymphocyte subsets in IgA nephropathy. Clin Exp Immunol. 1994; 96(1):116-21. PMC: 1534550. DOI: 10.1111/j.1365-2249.1994.tb06240.x. View

3.
Monteiro R, Kubagawa H, Cooper M . Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humans. J Exp Med. 1990; 171(3):597-613. PMC: 2187784. DOI: 10.1084/jem.171.3.597. View

4.
Smith A, Molyneux K, Feehally J, Barratt J . O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol. 2006; 17(12):3520-8. DOI: 10.1681/ASN.2006060658. View

5.
Grossetete B, Launay P, Lehuen A, Jungers P, Bach J, Monteiro R . Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int. 1998; 53(5):1321-35. DOI: 10.1046/j.1523-1755.1998.00885.x. View